- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02822703
Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation (rTMS)
Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation (rTMS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project seeks to improve scientific knowledge of the decision-making processes of smokers and improve tobacco dependence treatments. The dorsolateral prefrontal cortex (DLPFC) influences decision-making by integrating inhibitory mechanisms with emotionally charged information from limbic regions, thereby exerting an inhibitory influence on seductive, immediately rewarding options with long-term costs, such as smoking. Delay discounting is the degree to which one de-values delayed outcomes, such as future health and long life. Converging evidence indicates that choosing a delayed option with a larger reward is associated with increased activity in the DLPFC. This study proposes that choosing to smoke after making a decision to quit reflects a situation where the DLPFC is insufficiently activated to exert an inhibitory influence on the immediately rewarding option of smoking.
Preliminary studies indicate that stimulation of the DLPFC with 20 Hz high frequency repetitive Transcranial Magnetic Stimulation (rTMS) reduces delay discounting (i.e., causes individuals to choose delayed, higher value options); reduces cigarette consumption in smokers intending to quit; improves executive function, learning, memory, and attention; is a promising adjunct to cognitive-behavioral treatment of other disorders; and is likely to improve the efficacy of existing cognitive-behavioral treatments for tobacco dependence.
The goal of this study is to make an informed recommendation, based on measures of feasibility, of whether or not this intervention should be tested for efficacy. A double blind, randomized between-subjects treatment (active or sham) design will be employed in which all subjects are exposed to the same relapse prevention materials during rTMS stimulation.
Aim 1: Examine the feasibility of combining high frequency rTMS with an evidence-based, self-help, cognitive-behavioral relapse prevention intervention using multiple feasibility indicators (demand, acceptability, practicality, limited-efficacy testing, and adequate blinding).
Aim 2: Examine differences in delay discounting between the active and the sham conditions 2, 4, 8, and 12 weeks after the quit day.
Aim 3: Use latency to relapse comparisons to calculate estimates of the effect size of this intervention on abstinence.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10031
- The City College of New York
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 21-65 years old
- Are fluent in English and be able to read English at the 8th grade level
- Pass the Transcranial Magnetic Stimulation Adult Safety and Screening Questionnaire (TASS)
- Report smoking 5-20 cigarettes daily
- Intend to quit smoking in the next 30 days
- Report a motivation level to quit of ≥7 (scale 0-10)
- Pass a urine drug screen for drugs of abuse (marijuana, cocaine, opioids, amphetamines, etc.)
- No plans to move from the area NYC area in the next 4 months and have a consistent, reliable method of communication so that study staff can successfully contact them
Exclusion Criteria:
- self-reported claustrophobia
- personal history of epilepsy
- use of anticonvulsant medication
- head injury, aneurysm, stroke, or previous cranial neurosurgery
- diagnosis of major depressive disorder, bipolar disorder, a schizophrenia-spectrum disorder, tinnitus, or migraines
- metal implants in the head, neck, or cochlea; a pacemaker
- currently taking medications that lower seizure threshold (i.e., such as tricyclic antidepressants or bupropion)
- known pre-existing noise induced hearing loss or concurrent treatment of ototoxic medications (i.e., Aminoglycosides, Cisplatine)
- currently using medications for tobacco cessation (i.e., nicotine replacement, bupropion, varenicline, etc.)
- pregnant or planning to become pregnant in the next 12 weeks
- current regular use of forms of tobacco other than cigarettes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active 20Hz
The rTMS device used in this study is the Mastim Super Rapid2 Stimulator with a 70mm Double Air Film Coil.
Guidelines indicate that the maximum safe duration of a single train of 20Hz at 110% of the Motor Threshold (MT) is 1.6 seconds.
In this study, the stimulator and the coils will be used to stimulate neurons in the left dorsolateral prefrontal cortex (DLPFC), the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment in depression, in order to examine the feasibility of testing this intervention for efficacy in the treatment of tobacco dependence.
|
Active stimulation will be delivered with 70mm Double Air Film Coils.
Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date.
Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines.
These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers.
These parameters are similar to or less intense than those utilized in other smoking cessation studies.
All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
|
Sham Comparator: Sham
The rTMS sham coil used in this study is manufactured by Magstim and currently classified as an investigational device.
There is no intention to treat or prevent a disease and/or alter a function in the body with the sham stimulation provided by the sham coil.
In this project, the sham coil will be placed in the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment for depression.
|
The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive.
Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date.
During these sessions, they will also read relapse prevention booklets supervised by the study coordinator.
The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Latency to relapse
Time Frame: 3.5 months following scheduled quit date
|
Abstinence will be assessed with latency to relapse (days from Quit Date to relapse or 7 consecutive days of smoking after a 24 hour quit attempt)
|
3.5 months following scheduled quit date
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christine E Sheffer, PhD, CCNY
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 639308
- R21CA178813 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on rTMS Active 20Hz
-
Centre for Addiction and Mental HealthYale University; Oregon State UniversityWithdrawnSchizophrenia | Tobacco Use Disorder | Craving | Cognitive Functioning
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Seoul National University HospitalUnknownTinnitusKorea, Republic of
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University of Maryland, BaltimoreRecruiting
-
Gaziler Physical Medicine and Rehabilitation Education...Active, not recruitingChronic StrokeTurkey
-
Centre Hospitalier du RouvrayUniversity Hospital, Rouen; Centre Hospitalier Sainte Anne, ParisNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityNot yet recruitingBrain Injuries | Gut Microbiota | Respiratory Function Impaired
-
Massachusetts General HospitalNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingLogopenic Variant Primary Progressive Aphasia | Non-fluent Variant Primary Progressive Aphasia | Semantic Variant Primary Progressive AphasiaUnited States
-
Stanford UniversityNational Institute on Drug Abuse (NIDA)CompletedCannabis Use DisorderUnited States